Batches of prevalent hypertension medicine taken off the market

hypertension medicine

The business Torrent Pharmaceuticals Ltd. announces that they will withdraw more batches of the popular hypertension drug Losartan after finding that in January of this year they contained unacceptably elevated concentrations of a carcinogen.

Losartan is a drug that physicians frequently use in individuals with or without left ventricular hypertrophy to treat high blood pressure, an abnormal enlargement of the left ventricle of the heart. Losartan is also prescribed for the therapy of nephropathy in individuals with type 2 diabetes by health care professionals. The drug is being marketed by Torrent Pharma, which also runs through Torrent Pharma.

Recently, the firm has willingly withdrawn some Losartan batches from the market as they contained traces of impurity at concentrations considered unsafe by the Food and Drug Administration (FDA). Several “extension recalls” have been announced since then, withdrawing more batches of the drug.

Now, the FDA has released a fifth extension recall for Losartan potassium tablets, USP, including Losartan potassium/hydrochlorothiazide tablets, USP, for the company. NDEA is a hepatotoxic agent, which implies it damages the liver, according to the National Library of Medicine. They also say that causing cancer in humans is “reasonably expected.” It is necessary to continue the treatment.

Importantly, the pharmaceutical company recommends that individuals who already take these medicines continue to do so because an abrupt interruption of therapy without an alternative backup can pose a higher health risk.

The firm recommends that individuals who are presently taking the drug seek guidance from their pharmacists or doctors on alternative therapy before stopping taking the drug. The FDA website contains a table listing the names and batch numbers of the recalled products, making it easier to identify them.

The FDA adds that they post recall advertisements by businesses as a matter of public health and service and that advertising the announcement by Torrent Pharmaceuticals does not endorse the product or the business.